- Home
- DMF vs EDIT Comparison
DMF vs EDIT Comparison
Compare DMF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- EDIT
- Stock Information
- Founded
- DMF 1988
- EDIT 2013
- Country
- DMF United States
- EDIT United States
- Employees
- DMF N/A
- EDIT N/A
- Industry
- DMF Finance/Investors Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMF Finance
- EDIT Health Care
- Exchange
- DMF Nasdaq
- EDIT Nasdaq
- Market Cap
- DMF 143.6M
- EDIT 156.5M
- IPO Year
- DMF N/A
- EDIT 2016
- Fundamental
- Price
- DMF $6.93
- EDIT $2.25
- Analyst Decision
- DMF
- EDIT Buy
- Analyst Count
- DMF 0
- EDIT 13
- Target Price
- DMF N/A
- EDIT $6.73
- AVG Volume (30 Days)
- DMF 60.7K
- EDIT 2.4M
- Earning Date
- DMF 01-01-0001
- EDIT 08-06-2025
- Dividend Yield
- DMF 2.66%
- EDIT N/A
- EPS Growth
- DMF N/A
- EDIT N/A
- EPS
- DMF 0.15
- EDIT N/A
- Revenue
- DMF N/A
- EDIT $35,837,000.00
- Revenue This Year
- DMF N/A
- EDIT N/A
- Revenue Next Year
- DMF N/A
- EDIT N/A
- P/E Ratio
- DMF $45.13
- EDIT N/A
- Revenue Growth
- DMF N/A
- EDIT N/A
- 52 Week Low
- DMF $5.37
- EDIT $0.91
- 52 Week High
- DMF $6.79
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- DMF 45.82
- EDIT 63.76
- Support Level
- DMF $6.86
- EDIT $2.05
- Resistance Level
- DMF $6.97
- EDIT $2.55
- Average True Range (ATR)
- DMF 0.05
- EDIT 0.23
- MACD
- DMF 0.00
- EDIT 0.03
- Stochastic Oscillator
- DMF 61.04
- EDIT 66.29
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.